甲状腺功能亢进症三种治疗方式与死亡风险:系统综述与网络Meta分析
该系统综述与网络Meta分析纳入12项观察性研究共192,208例甲亢患者,比较抗甲状腺药物、放射性碘和手术治疗与全因死亡、心血管死亡、主要不良心血管事件及癌症死亡的关联。结果显示手术较药物和放射性碘显著降低全因死亡和心血管死亡风险,但主要不良心血管事件和癌症死亡无显著差异。
要点
- 主要不良心血管事件和癌症死亡在各治疗组间无显著差异。
核心结论
- 在甲亢患者中,手术较抗甲状腺药物和放射性碘与全因死亡及心血管死亡风险显著降低相关。
- 主要不良心血管事件和癌症死亡风险在不同治疗方式间无显著差异。
研究设计与样本
- 系统综述与网络Meta分析,检索PubMed、EMBASE、Web of Science和Cochrane Library(建库至2025年3月7日)。
- 纳入12项观察性研究,共192,208例甲亢患者,总体偏倚风险为中等。
主要发现
- 主要不良心血管事件和癌症死亡在各治疗组间无显著差异。
临床怎么用
- 对于甲亢患者,选择手术而非抗甲状腺药物或放射性碘可能降低全因死亡和心血管死亡风险。
- 主要不良心血管事件和癌症死亡风险不因治疗方式不同而显著改变。
局限性
- 纳入研究均为观察性研究,存在异质性和潜在选择偏倚等方法学局限。
- 结果需谨慎解读,不能直接推断因果关系。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Introduction: Hyperthyroidism can be treated with antithyroid drugs (ATD), radioactive iodine (RAI), or surgery. We aimed to evaluate the long-term outcomes of these treatments through a systematic review and network meta-analysis (NMA). Methods: A systematic literature search of PubMed, EMBASE, Web of Science, and the Cochrane Library (from inception to March 7, 2025) was conducted to identify studies comparing the risks of all-cause mortality, cardiovascular mortality, major adverse cardiovascular events (MACE), and cancer mortality among patients with hyperthyroidism treated with ATD, RAI, or surgery. Pooled effect estimates were expressed as hazard ratios (HR) with confidence intervals (CI) using a random-effects model. The study was registered with PROSPERO (CRD420250543380) and adhered to the PRISMA-NMA guidelines. Results: Of the 8163 studies screened, 12 observational studies with an overall moderate risk of bias, comprising 192,208 patients were included in this NMA. Most patients received ATD (n = 142,622), followed by RAI (n = 19,303) and surgery (n = 10,360). Surgery was associated with decreased risks of all-cause mortality and cardiovascular mortality compared with both ATD and RAI. For all-cause mortality, the pooled HRs (CI, p-values) were 0.58 (0.45-0.75, p < 0.0001) for surgery versus ATD and 0.68 (0.56-0.84, p = 0.0004) for surgery versus RAI. For cardiovascular mortality, the pooled HR (CI, p-values) were 0.43 (0.19-0.98, p = 0.0445) for surgery versus ATD and 0.55 (0.33-0.93, p = 0.0269) for surgery versus RAI. No significant differences were observed in MACE or cancer mortality across the treatment groups. Conclusions: In patients with hyperthyroidism, surgery was associated with significantly decreased risks of all-cause mortality and cardiovascular mortality compared with ATD and RAI. Risks of MACE and cancer mortality did not differ by type of hyperthyroidism treatment. However, these findings should be interpreted with caution due to inherent methodological limitations of observational studies, including, but not limited to heterogeneity and potential selection bias.
引用
- Peng CC, Spiegel BR, Flynn D, et al. Mortality Risks Associated with Antithyroid Drugs, Radioactive Iodine, and Surgery for Hyperthyroidism: A Systematic Review and Network Meta-Analysis. Thyroid. 2025. PMID: 40891035. doi:10.1177/10507256251372193
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。